Sugi Predict

Sugi Predict / Compounds / SCHEMBL4259978

SCHEMBL4259978

SCHEMBL4259978

O=C(O)c1cc(-c2ccccc2)nc(-c2ccccc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTRC Q99895 3/20 0.77
▸ MCL1 Q07820 1/20 0.61
▸ LDHA P00338 1/20 0.55
▸ KDM4E B2RXH2 3/20 0.55
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ LMNA P02545 1/20 0.55
▸ PDE10A Q9Y233 1/20 0.55
▸ TP53 P04637 1/20 0.53
▸ ADORA1 P30542 2/20 0.53
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ NTSR1 P30989 1/20 0.52
▸ DHODH Q02127 1/20 0.51
▸ NPC1 O15118 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ KMO O15229 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ ADORA3 P0DMS8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7675313 0.88 CTRC (0.63) CTRCMCL1LDHAKDM4ESMN1; SMN2
SCHEMBL10917470 0.88 CTRC (1.00) CTRCMCL1KDM4ESMN1; SMN2MEN1
SCHEMBL10916829 0.88 MCL1 (0.76) CTRCMCL1DHODHALDH1A1
SCHEMBL31388676 0.87 CTRC (0.66) CTRCMCL1KDM4ESMN1; SMN2TP53
SCHEMBL12551315 0.87 CTRC (0.61) CTRCMCL1KDM4ESMN1; SMN2LMNA
SCHEMBL20346112 0.87 CTRC (0.61) CTRCMCL1LDHAKDM4ESMN1; SMN2
SCHEMBL18363001 0.87 CTRC (0.61) CTRCMCL1LDHAKDM4ESMN1; SMN2
SCHEMBL7675294 0.87 CTRC (0.71) CTRCMCL1LDHAKDM4ESMN1; SMN2
SCHEMBL28268713 0.86 KDM4E (0.66) CTRCMCL1LDHAKDM4ESMN1; SMN2
SCHEMBL8480344 0.84 CTRC (0.68) CTRCMCL1LDHAKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11225480-B2 Malic enzyme inhibitors SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-01-18 — — US disclosed
US-20210115038-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2021-04-22 — — US disclosed
US-10711027-B2 DNA polymerase beta inhibitors THE JOHNS HOPKINS UNIVERSITY (US) 2020-07-14 — — US disclosed
US-20190202853-A1 DNA POLYMERASE BETA INHIBITORS THE JOHNS HOPKINS UNIVERSITY 2019-07-04 — — US disclosed
US-9884863-B2 STAT3 inhibitor BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-02-06 — — US disclosed
US-9884863-B2 STAT3 inhibitor BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-02-06 — — US disclosed
US-9884863-B2 STAT3 inhibitor BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-02-06 — — US disclosed
US-20170152260-A1 STAT3 INHIBITOR BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-06-01 — — US disclosed
US-20170152260-A1 STAT3 INHIBITOR BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-06-01 — — US disclosed
US-20170152260-A1 STAT3 INHIBITOR BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-06-01 — — US disclosed
US-20070037974-A1 Inhibitors of P2X3 ROCHE PALO ALTO LLC 2007-02-15 — — US disclosed
US-6979741-B2 Acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2005-12-27 — — US disclosed
EP-1478437-B1 ACC INHIBITORS PFIZER PROD INC (US) 2005-08-31 — — EP disclosed
CN-1642599-A ACC inhibitors PFIZER PROD INC (US) 2005-07-20 — — CN disclosed
EP-1478437-A1 ACC INHIBITORS Pfizer Products Inc. (US) 2004-11-24 — — EP disclosed
US-20030187254-A1 Acetyl-CoA carboxylase inhibitors PFIZER INC. 2003-10-02 — — US disclosed
WO-2003072197-A1 ACC INHIBITORS PFIZER PRODUCTS INC. (US) 2003-09-04 — — WO disclosed
EP-0064385-B1 2,6-DIARYL-PYRIDINECARBOXYLIC ACIDS AND THEIR THERAPEUTIC UTILITY THE UPJOHN COMPANY (US) 1986-04-02 — — EP disclosed
US-4377586-A Diuretic 2,6-diaryl-4-pyridine carboxylic acids THE UPJOHN COMPANY (US) 1983-03-22 — — US disclosed
EP-0064385-A1 2,6-Diaryl-pyridinecarboxylic acids and their therapeutic utility THE UPJOHN COMPANY (US) 1982-11-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10711027-B2 DNA polymerase beta inhibitors POLB, POLH, POLN CTRC 2255/4885MCL1 1259/4885LDHA 480/4885
US-20210115038-A1 MALIC ENZYME INHIBITORS ME1, ME2, ME3 CTRC 879/4885MCL1 1940/4885LDHA 110/4885
US-20070037974-A1 Inhibitors of P2X3 P2RX3, P2RX4, P2RX5 CTRC 1936/4885MCL1 4262/4885LDHA 3727/4885
US-11225480-B2 Malic enzyme inhibitors ME1, RNASE1, ME2 CTRC 601/4885MCL1 3028/4885LDHA 132/4885
US-20170152260-A1 STAT3 INHIBITOR STAT3, STAT1, STAT4 CTRC 3008/4885MCL1 1185/4885LDHA 3548/4885
US-20190202853-A1 DNA POLYMERASE BETA INHIBITORS POLB, POLH, POLN CTRC 2255/4885MCL1 1259/4885LDHA 480/4885
US-20030187254-A1 Acetyl-CoA carboxylase inhibitors ACACA, ACACB, ACAT1 CTRC 1337/4885MCL1 3759/4885LDHA 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.